Catalyst
Slingshot members are tracking this event:
Portola Pharmaceuticals (NASDAQ: PTLA) receives Complete Response Letter (CRL) from FDA for BLA for Andexxa, an antidote for bleeding related to factor Xa inhibitors (8/17/2016).
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 17, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Factor Xa Inhibitor, Frequent Bleeding Episodes
